Inactive Instrument

Lansen Pharmaceutical Holdings Limited

503 KYG5380M1033

Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2021

August 31, 2021 at 10:35 am EDT

Lansen Pharmaceutical Holdings Limited announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was USD 23.485 million compared to USD 26.776 million a year ago. Operating income was USD 2.781 million compared to USD 5.992 million a year ago. Net income was USD 1.529 million compared to USD 96.442 million a year ago. Basic earnings per share from continuing operations was USD 0.0038 compared to USD 0.243 a year ago.

Latest news about Lansen Pharmaceutical Holdings Limited

Lansen Pharmaceutical to Delist from HKEX on Dec. 19	Dec. 18	MT
Cayman Islands Court Approves Takeover, Privatization of Lansen Pharma	Dec. 15	MT
Cathay International Holdings Limited completed the acquisition of additional 31.78% stake in Lansen Pharmaceutical Holdings Limited.	Dec. 14	CI
Cathay International Pharma to Privatize Lansen Pharmaceutical in HK$239 Million Deal	23-09-18	MT
Lansen Pharmaceutical's H1 Profit Slides 17%	23-08-24	MT
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Lansen Pharmaceutical Holdings Limited commences an Equity Buyback Plan for 42,243,243 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2023.	23-06-23	CI
Lansen Pharmaceutical Holdings Limited's Equity Buyback announced on June 24, 2022, has expired.	23-06-20	CI
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022.	23-03-24	CI
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Lansen Pharmaceutical Holdings Limited Declares Interim Dividend	23-03-24	CI
Lansen Pharmaceutical Expects 2022 Profit Soaring 798%; Shares Surge 22%	23-01-16	MT
Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022	23-01-15	CI
Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee	22-09-23	CI
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022.	22-08-31	CI
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
Lansen Pharmaceutical Holdings Limited commences an Equity Buyback Plan for 42,683,400 shares, representing 10% of its issued share capital, under the authorization approved on June 23, 2022.	22-06-24	CI
Lansen Pharmaceutical Holdings Limited Approves to Elect Chan Ching Har, Eliza as an Independent Non-Executive Director	22-06-23	CI
Lansen Pharmaceutical Holdings Limited's Equity Buyback announced on June 2, 2021, has expired.	22-06-22	CI
Lansen Pharma Sees Better Financial Performance in H1	22-06-15	MT
Lansen Pharmaceutical Holdings Limited Announces Resignation of Stephen Burnau Hunt as Non-Executive Director and Member of the Remuneration Committee	22-04-11	CI
Hong Kong Stocks Edge Up after Wall Street Gains; Lansen Pharma Jumps 13%	22-04-08	MT
Lansen Pharma to Raise Nearly $8 Million From Private Placement; Shares Jump 12%	22-04-08	MT
Lansen Pharmaceutical Holdings to Seek Acquisitions	22-04-07	CI
Lansen Pharmaceutical Holdings Limited Announces Establishment of Nomination Committee and Appointment of Chairman and Members of the Nomination Committee	22-03-23	CI

Chart Lansen Pharmaceutical Holdings Limited

Duration

Period

Chart Lansen Pharmaceutical Holdings Limited

More charts

Company Profile

Lansen Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company operates through three segments. Specialty Pharmaceuticals segment is engaged in the development, production and sales of specialty pharmaceuticals mainly used in the fields of rheumatology and dermatology. Its main specialty pharmaceutical products include pafulin, leflunomide tablets and mycophenolate mofetil dispersible tablets. Plant Extract and Healthcare Products segment is engaged in the development, production and sales of Chinese medicine extracts and healthcare products. Other Pharmaceuticals segment is engaged in businesses related to other pharmaceuticals.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals